Table 2.
Detailing the results of serological testing (with dates) for diverse tested populations (and different test methodologies): focus on IgM and IgG positivity for COVID-19. Scandinavian and other countries. March to June (inclusive) 2020.
| Country | Date (2020) | % SERO + ve (IgM/IgG) | Population tested | Reference citation |
|---|---|---|---|---|
| Sweden | ||||
| Malmo | April | 4% | General | 18 |
| Stockholm | April | 17% | General | 18 |
| Germany | ||||
| Gangelt | April | 14% | General (super-spreader event) | 19 |
| U | ||||
| East | April-May | 5% | General | 20 |
| London | April-May | 17% | General | 20 |
| Denmark | April | 2% | All Danish blood donors | 21 |
| USA | ||||
| New York State | April | 12.3% | General | 22 |
| New York City | May/June | 21.6% | General | 22 |
| Switzerland | ||||
| Geneva | April-May | 5%–10% | Bus Sante screening study | 23 |
| China | ||||
| Wuhan | March | 3% | General | 24 |
A very recent report from Spain also high-lights the lack of significant Ab production in a large studied population of over 60,000 infected people (ENE-COVID study). Published:July 06, 2020 DOI:https://doi.org/10.1016/S0140-6736(20)31483-5.